SynthesisFrontiers in pharmacology2026
Protective and nephrotoxic effects of emodin in animal models of kidney injury: a systematic review and meta-analysis.
Synthesis in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Kidney injury is a growing global health problem with limited treatments. Emodin, an anthraquinone found in traditional Chinese medicinal herbs, shows both renoprotective and nephrotoxic effects in animal studies. This study aimed to systematically assess the effects of emodin on kidney injury Methods: A pre-registered systematic review and random-effects meta-analysis was conducted, focusing exclusively on Results: From 2,915 records, 24 studies (408 animals: 396 rodents, 12 canines) met inclusion criteria (17 therapeutic, 7 toxicity). In kidney injury models, emodin significantly reduced BUN (n = 182; SMD = -2.39; 95% CI -3.54 to -1.25; Conclusion: Emodin exhibits dual effects on the kidney, with its net outcome determined primarily by dosage, administration route, and treatment duration. These findings underscore the need for precise dosing and exposure control in the further development of emodin as a renal therapeutic agent. Systematic Review Registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261326554, identifier CRD420261326554.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.